MEREO BIOPHARMA GROUP PL-ADR (MREO) Stock Price & Overview
NASDAQ:MREO • US5894921072
The current stock price of MREO is 0.3919 USD. Today MREO is down by -2.02%. In the past month the price increased by 3.02%. In the past year, price decreased by -84.74%.
MREO Key Statistics
- Market Cap
- 62.364M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.26
- Dividend Yield
- N/A
MREO Stock Performance
MREO Stock Chart
MREO Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MREO. When comparing the yearly performance of all stocks, MREO is a bad performer in the overall market: 99.2% of all stocks are doing better.
MREO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MREO. MREO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MREO Earnings
MREO Forecast & Estimates
14 analysts have analysed MREO and the average price target is 1.79 USD. This implies a price increase of 355.47% is expected in the next year compared to the current price of 0.3919.
MREO Groups
Sector & Classification
MREO Financial Highlights
Over the last trailing twelve months MREO reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS increased by 36.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.77% | ||
| ROE | -89.46% | ||
| Debt/Equity | 0 |
MREO Ownership
MREO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.38 | 401.392B | ||
| AMGN | AMGEN INC | 16.46 | 202.383B | ||
| GILD | GILEAD SCIENCES INC | 16.67 | 184.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.37 | 126.804B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.63 | 81.619B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.66 | 42.754B | ||
| INSM | INSMED INC | N/A | 31.007B | ||
| NTRA | NATERA INC | N/A | 28.197B | ||
| BIIB | BIOGEN INC | 11.83 | 27.651B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.98 | 23.485B | ||
| MRNA | MODERNA INC | N/A | 21.714B | ||
| EXAS | EXACT SCIENCES CORP | 339.9 | 19.732B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.591B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MREO
Company Profile
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
Company Info
IPO: 2016-06-09
MEREO BIOPHARMA GROUP PL-ADR
One Cavendish Place, Fourth Floor
London W1G0QF GB
CEO: Denise Scots-Knight
Employees: 36
Phone: 443330237300
MEREO BIOPHARMA GROUP PL-ADR / MREO FAQ
What does MEREO BIOPHARMA GROUP PL-ADR do?
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. The firm has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). In addition to the rare disease programs, it has two oncology product candidates in clinical development, which include Etigilimab, an IgG1 monoclonal antibody which binds to the human T-cell immunoreceptor with Ig and ITIM domains (TIGIT) receptor on immune cells to improve the activation and effectiveness of T-cell and NK cell antitumor activity and Navicixizumab is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Navicixizumab is developed for the treatment of late-line ovarian cancer.
Can you provide the latest stock price for MEREO BIOPHARMA GROUP PL-ADR?
The current stock price of MREO is 0.3919 USD. The price decreased by -2.02% in the last trading session.
What is the dividend status of MEREO BIOPHARMA GROUP PL-ADR?
MREO does not pay a dividend.
How is the ChartMill rating for MEREO BIOPHARMA GROUP PL-ADR?
MREO has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about MEREO BIOPHARMA GROUP PL-ADR (MREO) stock?
14 analysts have analysed MREO and the average price target is 1.79 USD. This implies a price increase of 355.47% is expected in the next year compared to the current price of 0.3919.
What is the Price/Earnings (PE) ratio of MEREO BIOPHARMA GROUP PL-ADR (MREO)?
MEREO BIOPHARMA GROUP PL-ADR (MREO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).
What is the market capitalization of MREO stock?
MEREO BIOPHARMA GROUP PL-ADR (MREO) has a market capitalization of 62.36M USD. This makes MREO a Micro Cap stock.